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Abstract There is growing recognition that chemotherapy
may have short and long term impact on cognitive function
of cancer patients. However, the impact of chemotherapy on
the cognition of adult patients with primary brain tumor has
not been extensively studied. This article will review the
evidence for both positive and negative impact of chemo-
therapy on cognitive function of adult brain tumor patients
as well as potential confounding factors.
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Introduction
The impact of chemotherapy on cognitive outcomes of
cancer survivors is increasingly recognized and frequently
referred to as ‘‘chemo brain’’ [1]. While this concept has
gained popularity it is still being defined and verified. First
described in the 1980s most early reports were attributed to
patients surviving aggressive therapy for breast cancer and
lymphoma. Initial descriptions were largely based on self-
reporting by patients who described difficulties with mem-
ory and concentration. Increasingly studies and reports have
become more rigorous with prospective neuro-cognitive
assessments that document pre and post treatment deficits
across multiple domains [2]. Although attention, concen-
tration and memory remain primary areas of impairment
other cognitive dimensions are also recognized as having
been affected by chemotherapy such as visuo-spatial and
primary visual pathways [3].
The mechanism of injury by which chemotherapy
results in cognitive loss is not known and is likely to vary
according to the specific agent used. In animal models
increased cell death or decreased cell division in the sub-
ventricular zone and dentate gyrus have been described
following exposure to carmustine, cisplatin, cytarabine and
methotrexate [4, 5]. These models suggest vulnerability of
neural stem cell populations with resultant cognitive
impact. Primary pathologic lesions including demyelina-
tion, inflammation and microvascular injury have all been
postulated as mechanisms underlying neurotoxicity of
therapy [6]. Synergistic injury may occur with concomitant
or sequential administration of brain radiotherapy and
chemotherapy because of alterations in blood brain barrier
permeability and drug distributions. Finally a recent report
suggests that brain volume may decrease following
myeloablative chemotherapy prior to stem cell transplant in
leukemia and multiple sclerosis patients [7].
While ‘‘chemo brain’’ is increasingly recognized in
patients with cancer other than breast cancer and lym-
phoma the question for this manuscript is whether or not
adult brain tumor patients are at risk for significant cog-
nitive sequelae of chemotherapeutic treatment. This topic
has not been extensively explored in the past in large part
due to the poor prognosis of brain tumor patients and the
relative lack of effective chemotherapeutic agents.
Confounding factors
Before considering whether or not brain tumor patients suffer
adverse consequences of chemotherapy administration it is
important to consider the other factors that impact cognitive
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function in this patient population. Tumor location is perhaps
the most obvious consideration. The majority of primary
brain tumors are located in the cerebral hemispheres and have
an impact on some aspect of intellectual function. Although
this may be subtle or unrecognized by the patient, family and
treating physician, particularly during the acute phase of
diagnosis and early treatment, it may be increasingly appar-
ent in the long-term survivor who attempts to return to work
or full level of activity following successful treatment [8].
Age is a critical consideration in assessment of cognition.
The average age of diagnosis for glioblastoma, the most
common primary brain tumor of adults, is 60 years. Normal
persons in this age range may experience some normal
slowing of information processing and retrieval as well as
complaints of short-term memory loss. Furthermore in older
patients, co-morbidities and associated medications may
have a direct or indirect impact on cognition that must be
considered. Finally as MR imaging is often used as a sur-
rogate measure of neurotoxicity it must be recognized that
nonspecific white matter changes are seen with increasing
frequency according to patient age. In fact, age was one of
the strongest determinants of cognitive outcome in a series
of 79 primary brain tumor patients assessed at UCLA [9].
The presence or absence of both seizures and anti-epi-
leptics medications is another important consideration in
the assessment of cognitive outcome. Approximately one
in three brain tumor patients will have a seizure during the
course of their illness and it is known that seizure activity
has a direct impact on cognitive function. Furthermore the
use of anti-epileptic drugs is known to cause psychomotor
slowing, decreased working memory and general cognitive
decline in patients with a primary brain tumor [10].
Other considerations include the presence of co-morbidities
with a direct impact on the CNS such as depression and
dementia. Supportive medications may also have a significant
impact on cognition. Corticosteroids are likely the biggest cul-
prit as they are the most frequently used and have a wide range
of CNS impacts from mood changes (mania and depression),
insomnia, psychosis and impaired memory [11, 12].
Finally the other definitive therapies used for manage-
ment of the brain tumor may result in long-term cognitive
sequelae. Surgical resection can alleviate acute neurologic
symptoms but may also result in permanent deficit from
local injury. Radiotherapy often has a delayed impact on
white matter and neurons that may result in acute or
delayed leukoencephalopathy with or without associated
cognitive dysfunction [10, 13].
Specific impact of chemotherapy
A number of different scenarios may be considered to
assess the impact of chemotherapy on cognitive outcome of
primary brain tumor patients. Although the use of che-
motherapy alone is an uncommon strategy for primary
brain tumors some patients with chemosensitive PCNSL or
oligodendroglioma have been successfully managed in this
fashion and provide some useful observations. Combina-
tions of chemotherapy and radiotherapy allow for insights
about sequence, specific agents and high-risk populations.
Finally the increasing use of neuro-cognitive testing as a
prospective endpoint in some clinical trials will allow more
confident analysis of the data and development of better
treatment strategies in the future.
Chemotherapy alone
Primary CNS lymphoma (PCNSL)
Altered mentation is one of the most frequent ways for a
patient with PCNSL to present. Indeed detailed neuro-
cognitive testing at baseline and prior to specific anti-tumor
treatment in PCNSL demonstrates that most patients have
impairment in one or more of the following domains:
attention, executive function, memory, psychomotor speed
or language (specifically naming or fluency) [14]. A
number of small studies have now been done that specifi-
cally incorporate prospective neuro-cognitive testing as
part of PCNSL clinical trials [15–21]. These studies have
consistently shown that patients either remain stable or
have clear cognitive improvement during the course of
initial chemotherapy provided that their tumor is respond-
ing to treatment. This includes trials with alternate and
intensive delivery strategies for chemotherapy such as
blood brain barrier disruption and dose intensive chemo-
therapy used for myeloablation [16, 22]. In long term fol-
low up of cognitive function it has been shown that PCNSL
patients treated with chemotherapy alone most often
remain cognitively stable although some studies have
reported minor or occasional declines in attention, memory
and verbal fluency [14].
One retrospective study compared cognitive outcome in
PCNSL patients treated at the same institution with either
chemotherapy alone or in combination with RT [23].
Twenty-four patients were treated with a combination of
chemotherapy and RT while 26 patients received chemo-
therapy alone. When controlling for age and time from
initial diagnosis the authors concluded that patients treated
with chemotherapy alone had substantially less impair-
ment than those treated with both chemotherapy and
radiotherapy. Furthermore the degree of impairment in
those patients treated with chemotherapy alone was
more likely to be within one standard deviation of the
norm suggesting a less significant impact on day-to-day
functioning.
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Anaplastic oligodendroglioma
There is growing evidence to suggest that patients with
anaplastic oligodendroglioma with deletion of 1p and/or
19q may be successfully treated with chemotherapy alone
as initial therapy [24, 25]. One motivation for this treatment
strategy comes from the fact that these tend to be young
patients often with large tumors and a relatively long life
expectancy. Therefore, the concept is that delaying or
deferring radiotherapy might minimize cognitive impact of
therapy. Despite this trend there has been little in the way of
prospective cognitive assessment in this patient population.
One study that treated such patients with chemotherapy
alone using a myeloablative chemotherapy regimen in
place of usual consolidation radiotherapy described that 21
long-term survivors had largely returned to their pre-mor-
bid career or level of function [26]. Two patients were
noted to have impairments ascribed to tumor but possibly
treatment related. A large ongoing intergroup trial in this
patient population will test chemotherapy alone as an initial
treatment strategy and prospective cognitive testing is
incorporated as a composite primary endpoint [27].
Low grade glioma
A recent recommendation from the EFNS–EANO task force
suggests that chemotherapy alone may be used as initial
therapy for patients with large residual or unresectable
tumor to delay the risk of late neurotoxicity associated with
large field radiotherapy, particularly when 1p and 19q loss is
present, based on level B evidence [28]. Similar to patients
with anaplastic oligodendroglioma, patients with low grade
glioma are often in the prime of their life and may live for
many years with their tumor; hence preservation of cogni-
tive function is a critical goal of therapy. Several studies
have suggested that chemotherapy may result in various
clinical improvements including improved seizure control,
neurologic function and quality of life [29–31]; however,
detailed neurocognitive evaluation of low grade glioma
patients treated with chemotherapy alone is sparse. Correa
et al. included three patients treated with chemotherapy
alone in a longitudinal analysis of cognitive function in low
grade glioma but this subset was too small to be critically
compared [32]. Increasingly there is a mandate for clinical
trials in this patient population to assess cognitive function
as a prospective endpoint [28, 33]. The ongoing EORTC-
NCIC study for low grade glioma includes a chemotherapy
alone arm and incorporates MMSE and QOL testing with
one objective to assess the delayed toxicity of temozolo-
mide alone [34]. Another ongoing cooperative group study
sponsored by ECOG will assess the addition of temozolo-
mide to radiotherapy for newly diagnosed low grade gli-
oma; a detailed neurocognitive substudy is planned [35].
Chemotherapy and radiotherapy
Most often patients with primary brain tumors are treated
with some combination of chemotherapy and radiotherapy.
These treatments may be given in sequence or concomi-
tantly. Depending on the underlying pathology, radiother-
apy dose and field, and particular chemotherapeutic agent
used, a variety of different outcomes may be anticipated.
Primary CNS lymphoma
PCNSL was one of the first primary brain tumors to herald
the risk of cognitive impact of therapy. Recognition of the
detrimental impact of combined chemoradiotherapy fol-
lowing the sequential administration of high dose MTX
and whole brain radiotherapy was first described in the
early 1990s. Although this combination was clearly supe-
rior to the use of radiotherapy alone in terms of disease
control and potential to extend survival, with prolonged
survival it became clear that survivors, particularly those
over the age of 60, were at high risk of treatment related
dementia [10, 14].
A detailed review of multiple studies in the literature
shows diffuse impairments in cognition following standard
combined therapy with high dose methotrexate and radio-
therapy [14]. The pattern of cognitive deficits spans mul-
tiple domains including attention and executive functions,
psychomotor speed, learning and retrieval of new infor-
mation. While the direct attribution of cognitive toxicity to
the individual components of therapy is not possible from
this data it seems likely that the particular sequence and
combination of methotrexate followed by whole brain
radiotherapy is largely responsible as opposed to either
component alone.
Anaplastic oligodendroglioma
Similar to PCNSL, patients with anaplastic oligodendro-
glioma have the potential for prolonged survival with
excellent disease control and this tumor particularly in the
setting of 1p and 19q deletion is known to be sensitive to
chemotherapy. Further, patients with oligodendroglioma
are often younger with a median age of 30–40 and there-
fore are in the prime of their working and productive life
making cognitive function of critical importance.
Several studies have looked at combinations of che-
motherapy and radiation to optimize disease control and
survival. In particular two recently published studies
compared radiation alone to radiation in combination with
PCV chemotherapy [36, 37]. Both studies found similar
survival for each treatment arm and confirmed the prog-
nostic impact of 1p and 19q deletion on overall survival.
While neither study included cognitive function as a
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prospective endpoint for patient outcomes each study
examined potential surrogate endpoints, such as mini
mental status examination, performance status and quality
of life. The RTOG study found that MMSE and brain
related quality of life were similar between the two treat-
ment arms [38]. However in both groups these scores
tended to decline overtime suggesting the potential for
chronic deleterious impact of therapy but not specific to
chemotherapy. It was also observed that better scores were
associated with improved survival. Similarly in the EO-
RTC study no significant difference in QOL was observed
between the two treatment groups outside of the acute
treatment interval suggesting no chronic negative impact
from the addition of chemotherapy [39].
Glioblastoma
Previously the survival of patients with newly diagnosed
GBM was too short to meaningfully assess the chronic or
cognitive impact of relatively ineffective or short-lived
therapies. However, increasingly therapies are available
which result in meaningful survival as evidenced by the
number of long-term survivors.
Assessment of long-term survivors reveals some
important observations that may be used to guide future
therapeutic strategies [40, 41]. One study of 39 GBM
patients with survival of 3y or more following initial
diagnosis showed that the majority of patients (85%) had
neurologic impairment, including at least 30% with cog-
nitive dysfunction [41]. Nine patients had evidence of a
cerebrovascular event, either ischemic or hemorrhagic, and
six had radiation-induced necrosis. It is important to con-
sider that most of these patients (72%) had been treated
both for their primary diagnosis of GBM as well as for
subsequent recurrence with a variety of therapies.
The addition of temozolomide during initial radiother-
apy has been the major change in standard of care over the
past decade [42]. Patients receiving this treatment have
more than double the possibility of surviving at 2 years as
compared with patients treated with radiation alone. This
treatment approach raises the question of the safety of
administration of concomitant chemoradiotherapy. From
the long term follow up of the pivotal study of the EORTC
there is little evidence to suggest additive or synergistic
toxicity resulting from this regimen [43]. Indeed, only three
patients out of the original cohort are reported as having
late treatment related toxicity at 5 years. Two patients in
the concurrent temozolomide and radiotherapy arm had
late toxicity—one patient with seizures and another with
visual deficit; one patient in the RT alone arm is reported to
have fatigue. These results are further supported by a small
prospective study from the Netherlands that directly
assessed cognitive function in newly diagnosed patients
being treated with this standard therapy [44]. Early
assessment during and immediately after the therapy found
that most patients were cognitively stable or improved;
however, long-term follow up was not available.
This new standard of care is currently under debate for
older patients. Patients over the age of 70 were not inclu-
ded in the original EORTC study. This is an important area
of consideration because older patients comprise a signif-
icant fraction of patients diagnosed with GBM. Further-
more this patient subset typically has a worse prognosis
and may be more vulnerable to the negative effects of
therapy. Several studies and reports have now demon-
strated that concomitant TMZ/RT may be an effective
therapy in older patients [45–48]. However a recent pro-
spective study suggests that there may be a significant risk
of toxicity among older patients treated with this regimen
[46]. Fifty-eight patients over the age of 65 were treated
with the standard of care and achieved excellent progres-
sion free and overall survival (9.5 and 13.7 months,
respectively) as compared with historic controls; however,
25% of patients developed grade 3–4 cognitive dysfunction
and 10% developed leukoencephalopathy. The authors
concluded that this rate of toxicity may be unacceptably
high and merits further study prior to recommending this
regimen as standard of care in older patients. Several other
reports have raised similar concerns of excess toxicity
among older patients treated with concurrent temozolo-
mide and RT [47, 48]; an ongoing intergroup study will
provide prospective data with regard to efficacy and tox-
icity in this population [49]. Of interest, a recent prospec-
tive study of temozolomide alone for frail patients over
70 years of age showed improvement of QOL and cogni-
tive function in responding or stable patients [50].
A recent study looked at neurocognitive outcome as an
exploratory endpoint for a trial of bevacizumab in recurrent
glioblastoma [51]. Using three standardized tests of spe-
cific cognitive domains the researchers were able to dem-
onstrate that neurocognitive status (worsened, stable, or
improved) correlated with radiographic tumor response and
disease control as measured by progression free survival.
This data suggests the possibility of incorporating neuro-
cognitive testing as an alternate measure of efficacy to
support imaging criteria. Neuro-cognitive function is being
used as an endpoint in several ongoing clinical trials of new
therapies for brain tumors.
Conclusions
At the present time there is little evidence to support a
serious concern for the risk of ‘‘chemo brain’’ among
patients with a primary brain tumor. While the acute
impact of chemotherapy may result in fatigue and apparent
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cognitive decline during the course of active therapy,
available data suggests that most patients with a positive
response to chemotherapy will also have cognitive stability
or improvement to mirror the anti-tumor effect. Data
regarding the long-term cognitive impact of chemotherapy
remains sparse. The best data from patients with PCNSL do
not support significant delayed or chronic neurotoxicity
induced by chemotherapy. Long term follow up of patients
with anaplastic oligodendroglioma that fail to suggest any
incremental decline in function among patients treated with
chemotherapy in addition to RT; but detailed cognitive
assessment following chemotherapy is not available for
these patients or those with low grade glioma. Emerging
data related to elderly patients with glioblastoma merit
additional study to exclude significant neurotoxicity as a
result of concomitant temozolomide and radiotherapy. Our
primary charge continues to be the discovery of more
effective therapies to control primary brain tumors as the
major risk to cognitive function at present is the presence
of active tumor either at diagnosis and recurrence.
Conflict of interest statement The author declares that she has no
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